Categories: Business

Glenmark Starts Phase III Clinical Trial of Antiviral Favipiravir Drug on COVID-19 Patients

Photo: GOOGLE

Glenmark initiates phase 3 clinical trials on antiviral favipiravir for COVID-19 patients

new Delhi. Glanmark Pharma has started a Phase III clinical trial of its antiviral tablet Favipiravir over corona virus infected patients in India. DCGI approved its trial in late April. Glanmark is the first company to start Favipiravir's Phase III clinical trial on Kovid-19 patients in India.

Clinical trials are being conducted in 10 government and private hospitals. Glanmark Pharma has predicted that the trial will be completed by July / August 2020. Glanmark has successfully designed APIs and formulations through its inhouse R&D team.

Favipiravir has performed well against influenza virus and in Japan it has been allowed to be used in the treatment of influenza virus infection. If it gets commercial approval it will be sold in India under the brand name FabiFlu.

Dr. Monica Tandon, Vice President of Glanmark Pharma and Head of Clinical Development, said that many health and medical experts are eager to see Favipiravir's effect on Kovid-19 patients. We are confident that the results of the study will be surprising as no effective medicine is yet available for treatment of corona virus. He said that the results from these tests will show us the way forward in the treatment and management of Kovid-19.

Glenmark is the first company to be approved by the regulator for testing on Kovid-19 patients in India. Under the approved clinical trial protocol, the duration of treatment would be a maximum of 14 days and the total duration of the study would be a maximum of 28 days.

This post was published on May 12, 2020 12:03 pm

Content Team

Recent Posts

We are going to become the world's largest 100% electrified rail network: Piyush Goyal

Photo: PTI There're clear signs that India is on path of getting back into action: Piyush Goyal at India Global…

ED raids Delhi NCR tour travel companies seized rs 3.57 crore. ED raids Delhi travel companies, seized Rs 3.57 crore

Photo: FILE ED raids Delhi NCR tour travel companies seized rs 3.57 crore New Delhi. The Enforcement Directorate (ED) has…